May 27, 2020
Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually
May 14, 2020
Pulmatrix Reports Q1 2020 Results
Mar 26, 2020
Pulmatrix Reports 2019 Financial Results and Provides Business Update
Feb 03, 2020
Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis
Jan 30, 2020
Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA
Jul 09, 2019
Pulmatrix Activates Sites for Pulmazole Phase 2 Clinical Study
Apr 15, 2019
Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole(TM)
Apr 01, 2019
Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole
Feb 07, 2019
Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study
Nov 21, 2018
Pulmatrix Announces Positive Final Results from the Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Nov 15, 2018
Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology
Aug 03, 2018
Pulmatrix Reports Q2 2018 Results
Jul 17, 2018
Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Jun 25, 2018
Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Mar 14, 2018
Laurent Pharmaceuticals reaches agreement with US Cystic Fibrosis Foundation to increase Development Award to $US 5M
Feb 12, 2018
Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Jan 24, 2018
Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018
Jan 22, 2018
Pulmatrix Announces Acceptance of a Clinical Trial Application in Europe for Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole
Nov 09, 2017
Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials
Oct 31, 2017
Pulmatrix Presents at the North American Cystic Fibrosis Conference